How To Check Senores Pharmaceuticals IPO Allotment Status? Find Latest GMP, Listing Date And More

Senores Pharmaceuticals IPO share allotment status is likely to be finalised on Thursday, Dec. 26, following a robust subscription.

The initial public offering of the pharmaceutical company was subscribed over 93.69 times at the end of the bidding on Dec. 24, according to NSE data. The Rs 582.11-crore issue had opened for subscription on Dec. 20.

Investors placed bids for 79,95,96,646 shares against 85,34,681 shares on offer. The issue was booked 96.30 times by non-institutional investors (NIIs) and 94.66 times by qualified institutional buyers (QIBs). The retail quota of the issue was subscribed 90.46 times.

The mainboard IPO combined a fresh issuance of 1.28 crore shares aggregating to Rs 500 crore and an offer-for-sale (OFS) option of 21 lakh shares, totalling Rs 82.11 crore. Senores Pharmaceuticals IPO price band was set at Rs 372 to Rs 379 apiece.

The minimum investment for the retail investors in the IPO was Rs 14,858 for a single lot size of 38 shares.

The investors, waiting for the Senores Pharmaceuticals IPO share allotment, can check the status online via the portals of BSE, NSE and the issue registrar, Link Intime India Pvt. Ltd.

• Visit the IPO allotment page on the BSE website here.

• Click on 'Equity' under the Issue Type.

• Select 'Senores Pharmaceuticals Limited' under the company name.

• Enter your application number or PAN.

• Clear the 'Captcha' to verify that you are not a robot.

• Select the 'Search' option to view your allotment status.

• Log on to the IPO allotment page on Link Intime India here. 

• From the dropdown list for company names, select 'Senores Pharmaceuticals Limited'.

• Choose any option from PAN, Application Number, DP/Client ID and Account Number/IFSC.

• Enter the required details based on your selection.

• Click on 'Submit' to check allotment details.

Investors also have the option to check the Senores Pharmaceuticals IPO allotment status by logging into their profile on NSE or creating a new registration.

Following the allotment, Senores Pharmaceuticals is scheduled to initiate the refunds for non-allottees and credit shares into the demat account of successful bidders on Dec. 27. Shares of Carraro India Ltd. are scheduled to list on the NSE and BSE on Monday, Dec. 30.

The grey market premium of Senores Pharmaceuticals IPO was Rs 240 as of 05:04 a.m. on Dec. 26, according to InvestorGain. This indicates a strong gain of 61.38% over the issue price with a listing price of Rs 631 apiece.

Note: GMP or grey market price is not an official price quote for the stock and is based on speculation.

Use Of Proceeds

Senores Pharmaceuticals Ltd. plans to use the net proceeds from the fresh issuance of shares in the IPO to invest in its subsidiary Havix Group Inc., which does business under the name of Aavis Pharmaceuticals. The investment will be made towards the set up manufacturing facility for the production of sterile injections at its Atlanta facility. Further, investments will also be made in Senores Pharmaceuticals' subsidiaries Havix, Senores Pharmaceuticals Inc. and Ratnatris Pharmaceutical Pvt. to fund working capital requirements and settle debts.  The company will also allocate the money for its working capital requirements and to fund inorganic growth through acquisition and other strategic initiatives.

About Senores Pharmaceuticals

The company is a global research-driven pharmaceutical company engaged in developing and manufacturing a wide range of generic pharmaceutical products. It primarily operates in the B2B segment, predominantly for the regulated markets across various therapeutic areas and dosage forms. Its regulated markets business is focused on the US, Canada and the United Kingdom.

Disclaimer: Investments in initial public offerings are subject to market risks. Please consult with financial advisors and read red herring prospectus thoroughly before placing bids.